STX

Novo Nordisk, Eli ⁣Lilly Weight-Loss Drugs Recommended as First-Line Obesity Treatments by European Doctors

LONDON, ⁤November 21, 2023 – Leading European doctors ​are advocating for a important shift in ‌obesity treatment‍ protocols, recommending that medications like ⁣Novo‍ NordiskS Wegovy and Eli Lilly‘s Mounjaro should be considered as ‍first-line options for ‌patients, rather than reserved for those who have failed to lose weight through diet and exercise alone. The‍ move signals ⁣a growing recognition of obesity⁢ as⁢ a chronic ​disease requiring medical intervention, similar to conditions⁤ like diabetes or hypertension.

For decades,lifestyle interventions have ⁤been the cornerstone of ⁣obesity management. Though, the limited long-term success rates of diet and exercise, coupled⁣ with⁣ the demonstrated efficacy of newer weight-loss drugs, are driving the⁢ call for ⁢a more aggressive and proactive approach. This shift coudl impact an estimated 50% of Europe’s adult population currently living with obesity, and ‌possibly ​alleviate the substantial ‍healthcare burden associated with related ​conditions like heart disease, type ​2 diabetes, and certain ⁢cancers.⁤

The proposal stems ‍from updated guidelines ⁣released this week by⁤ the⁢ European Association for the Study ‍of Obesity (EASO), reflecting a consensus among experts‍ that early pharmacological intervention can⁤ yield more substantial and‌ sustained weight ⁢loss, improving overall ​health outcomes.​ These drugs,known as GLP-1 receptor agonists,work by mimicking a natural hormone that regulates appetite and food intake.

“We are moving away from the idea ⁢that obesity is ‍a ‍matter⁢ of willpower,” explained Dr. Carel le Roux, EASO’s scientific advisor and professor of metabolic medicine at the University of Dublin, in⁤ a statement. “These medications are not a quick fix, but they‌ can ‌be a vrey effective tool when⁤ used in conjunction with lifestyle changes.”

Clinical trials​ have shown that Wegovy and Mounjaro can lead to weight losses of up to 20% of initial body weight, substantially exceeding the results⁣ typically achieved with ‌diet and exercise. While‍ potential side effects, such as ‌nausea and gastrointestinal discomfort, exist, doctors ⁢emphasize that the benefits often outweigh the risks for individuals with a body⁣ mass index (BMI) of 35 or higher, or those ‌with ⁢obesity-related health⁢ complications.

The updated guidelines ⁢also highlight the importance‌ of individualized⁢ treatment plans,considering factors such as patient preferences,co-existing medical conditions,and‍ potential drug interactions. Experts anticipate that wider‌ adoption‌ of these medications‌ as first-line treatments will ‍require‍ increased access, affordability, and ongoing monitoring to ensure patient ⁣safety and maximize effectiveness.